Inotiv, Inc. (NOTVQ) - Total Liabilities
Based on the latest financial reports, Inotiv, Inc. (NOTVQ) has total liabilities worth $625.32 Million USD as of March 2026. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.
Inotiv, Inc. - Total Liabilities Trend (1997–2025)
This chart illustrates how Inotiv, Inc.'s total liabilities have evolved over time, based on quarterly financial data. See how many days can Inotiv, Inc. fund operations to measure how many days the company can operate on defensive assets alone.
Inotiv, Inc. Competitors by Total Liabilities
The table below lists competitors of Inotiv, Inc. ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Bezant Resources Plc
LSE:BZT
|
UK | GBX1.35 Million |
|
Anexo Group Plc
LSE:ANX
|
UK | GBX115.42 Million |
|
Chelverton UK Dividend Trust PLC
LSE:SDV
|
UK | GBX173.00K |
|
HODL SPAC EUROPE AB
F:NW1
|
Germany | €6.13 Million |
|
GRIT Real Estate Income Group
LSE:GR1T
|
UK | GBX738.44 Million |
|
Hemogenyx Pharmaceuticals PLC
LSE:HEMO
|
UK | GBX3.65 Million |
|
ONETECH SOLUTIONS HOLDINGS BERHAD
KLSE:03041
|
Malaysia | RM3.90 Million |
|
Valion Bio Inc
NASDAQ:VBIO
|
USA | $14.81 Million |
Liability Composition Analysis (1997–2025)
This chart breaks down Inotiv, Inc.'s total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the complete balance sheet picture, see balance sheet size of Inotiv, Inc..
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 0.27 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 8.11 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.89 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Inotiv, Inc.'s debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Inotiv, Inc. (1997–2025)
The table below shows the annual total liabilities of Inotiv, Inc. from 1997 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-09-30 | $635.09 Million | +3.97% |
| 2024-09-30 | $610.86 Million | +3.88% |
| 2023-09-30 | $588.04 Million | -2.50% |
| 2022-09-30 | $603.13 Million | +178.29% |
| 2021-09-30 | $216.73 Million | +301.37% |
| 2020-09-30 | $54.00 Million | +72.68% |
| 2019-09-30 | $31.27 Million | +53.40% |
| 2018-09-30 | $20.38 Million | +70.58% |
| 2017-09-30 | $11.95 Million | -12.65% |
| 2016-09-30 | $13.68 Million | +4.46% |
| 2015-09-30 | $13.10 Million | -8.01% |
| 2014-09-30 | $14.24 Million | -11.77% |
| 2013-09-30 | $16.14 Million | -7.17% |
| 2012-09-30 | $17.39 Million | +3.73% |
| 2011-09-30 | $16.76 Million | -12.14% |
| 2010-09-30 | $19.08 Million | -2.00% |
| 2009-09-30 | $19.46 Million | -13.69% |
| 2008-09-30 | $22.55 Million | -3.96% |
| 2007-09-30 | $23.48 Million | -5.92% |
| 2006-09-30 | $24.96 Million | -11.62% |
| 2005-09-30 | $28.24 Million | +3.16% |
| 2004-09-30 | $27.38 Million | +8.38% |
| 2003-09-30 | $25.26 Million | +73.43% |
| 2002-09-30 | $14.56 Million | +43.54% |
| 2001-09-30 | $10.15 Million | -4.29% |
| 2000-09-30 | $10.60 Million | +19.11% |
| 1999-09-30 | $8.90 Million | +61.82% |
| 1998-09-30 | $5.50 Million | -38.89% |
| 1997-09-30 | $9.00 Million | -- |
About Inotiv, Inc.
Inotiv, Inc. provides nonclinical and analytical drug discovery and development services to the pharmaceutical and medical device industries in the United States, the Netherlands, and internationally. The company operates through two segments, Discovery and Safety Assessment (DSA) and Research Models and Services (RMS). The DMS segment manufactures scientific instruments for life sciences researc… Read more